No similar newsGo back to the news section
NPO Microgen (managed by Nacimbio holding of Rostec State Corporation) became the winner of National award in import substitution and technology transfer “Priority - 2019” in the nomination “Priority-Innovation” for the development of the first domestic combined three-component vaccine Vaktrivir for the prevention of measles, rubella and mumps. The new drug will allow using a more efficient vaccination schedule against three infections within the National Preventive Immunization Schedule.
The new vaccine is intended for immunization of adults and children over 12 months old and will allow reaching the immune defense effect from three causative agents at a time after only one injection. It is planned that the novelty will enter the market in 2020 and in the long run will completely cover the demand of the domestic public health in the population vaccination against measles, rubella and mumps. The project has a high social significance, since the use of combined vaccines meets the world trend in development of national programs for preventive immunization. This leads to the decrease of the injection burden, allows decreasing the burden on medical staff, improves the efficiency of Healthcare Service and forms compliance to vaccination.
The National award in import substitution and technology transfer “PRIORITY” is the only Russian reputable award since 2015 to the best representatives of the country who reached the greatest success in import substitution, localization, and export.
The award became a leading and permanent socially significant platform for companies participating in import substitution, provided them with high media and public interest having emphasized a particular importance of development of this branch of the Russian economy.